Screener
Summit Therapeutics SMMT EBITDA
Discontinued — last reported Q4 '24
EBITDA at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The source filing: Summit Therapeutics’s 10-K, filed February 23, 2026. Open the filing →
- Filed
- Feb 23, 2026, 4:10 PM EST
- Fiscal year
- FY2025
- Accession
- 0001599298-26-000015
FAQ
- What is Summit Therapeutics's EBITDA?
- Summit Therapeutics (SMMT) reported EBITDA of -$65.59M in Q4 2024.
- How has Summit Therapeutics's EBITDA changed year-over-year?
- Summit Therapeutics's EBITDA decreased by 81.3% year-over-year, from -$36.18M to -$65.59M.
- What is the long-term trend for Summit Therapeutics's EBITDA?
- Over 3 years (2021 to 2024), Summit Therapeutics's EBITDA has grown at a 38.6% compound annual growth rate (CAGR), from -$84.84M to -$225.91M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Summit Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude